Search

Your search keyword '"Kameoka, Yoshihiro"' showing total 308 results

Search Constraints

Start Over You searched for: Author "Kameoka, Yoshihiro" Remove constraint Author: "Kameoka, Yoshihiro"
308 results on '"Kameoka, Yoshihiro"'

Search Results

1. Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study

5. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL

8. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

14. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial

15. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin

18. Long‐term follow‐up after R‐High CHOP / CHASER / LEED with Auto‐PBSCT in untreated mantle cell lymphoma—Final analysis of JCOG0406

20. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum

26. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105

28. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

31. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.

32. Long‐term follow‐up after R‐High CHOP/CHASER/LEED with Auto‐PBSCT in untreated mantle cell lymphoma—Final analysis of JCOG0406.

34. Long‐term outcomes and central nervous system relapse in extranodal natural killer/T‐cell lymphoma

35. Thrombocytopenia Caused by a Tea Beverage of Taxus yunnanensis (Chinese Yew)

38. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.

39. Cooperative tracking in camera sensor networks with sliding mode control.

41. P-126: The prognostic impact of the UK Myeloma Research Alliance Risk Profile in untreated patients with multiple myeloma who received melphalan, prednisolone, and bortezomib: an ad hoc analysis of JCOG1105

42. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma: Verlag Dr. Kovac, ISBN: 978-3-8300-6328-5, 98,80 €

48. MO12-5 Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan

50. Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)

Catalog

Books, media, physical & digital resources